Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 983.74M | - |
| Gross profit | 365.09M | - |
| Net profit | 64.97M | - |
| EBITDA | 179.86M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €3.73B |
Number of shares | 432.92M |
52-week high/low | €8.99 - €4.70 |
| Dividends | No |
Next dividend | €0.13 |
Beta | 0.40 |
P/E ratio | 26.71 |
PEG ratio | -0.54 |
P/B ratio | 0.88 |
P/S ratio | 1.98 |
Company profile
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. The company was founded in 1850 and is headquartered in Durban, South Africa.
| Name | ASPEN PHAR.UN.ADR /1 O.N. ADR |
| CEO | Stephen Bradley Saad |
| Headquarters | Durban,
nl South Africa |
| Website | |
| IPO | 04/05/2010 |
| Employees | 7,625 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Frankfurt | LDZU.F |
Düsseldorf | LDZU.DU |